SA PRO
Free Account
ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
5 analysts·Limited coverage
100%
Rating Distribution
Strong Buy
00%
Buy
5100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 10, 2025BTIG
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential
Target:$45.00
+80.7%from $24.91
Nov 25, 2025Truist Financial
ArriVent Biopharma initiated with a Buy at Truist
Target:$43.00
+99.9%from $21.51
Jul 10, 2025Goldman Sachs
ArriVent Biopharma resumed with a Buy at Goldman Sachs
Target:$33.00
+49.8%from $22.03
Sep 10, 2024Citigroup
ArriVent BioPharma (AVBP) PT Raised to $36 at Citi
Target:$36.00
+28.9%from $27.93
Sep 10, 2024H.C. Wainwright
ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright
Target:$36.00
+28.4%from $28.04
Aug 16, 2024H.C. Wainwright
ArriVent BioPharma (AVBP) PT Raised to $30 at H.C. Wainwright
Target:$30.00
+27.0%from $23.62
Jul 22, 2024Oppenheimer
Oppenheimer Starts ArriVent BioPharma (AVBP) at Outperform
Target:$35.00
+86.5%from $18.77

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance